dyp688
dyp688: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: Novartis AG (NVS)
Development Pipeline (1)
| Company | Phase |
|---|---|
| Novartis AG (NVS) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas
Frequently asked questions
Who is developing dyp688?
dyp688 is being developed by Novartis AG.
How many clinical trials involve dyp688?
BioSniper tracks 1 clinical trial involving dyp688.
Analyze Novartis AG & dyp688 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company